Host: Marwan Noel Sabbagh, MD, FAAN, CCRI This series of micro-episodes will provide important information on slowing progression in mild cognitive impairment and early Alzheimers disease. Drs. Marwan Sabbagh and John Hardy discuss best practic

Host: Marwan Noel Sabbagh, MD, FAAN, CCRI This series of micro-episodes will provide important information on slowing progression in mild cognitive impairment and early Alzheimers disease. Drs. Marwan Sabbagh and John Hardy discuss best practic

Host: Professor Sir John Hardy This series of micro-episodes will provide important information on slowing progression in mild cognitive impairment and early Alzheimer’s disease. Drs. Marwan Sabbagh and John Hardy discuss best practices for reco

Host: Mazyar Shadman, MD, MPH Selection of Bruton’s tyrosine kinase (BTK) inhibitor therapy in CLL patients requires recognizing key differences between first- and next-generation agents in terms of the safety profile and efficacy across all pat

Host: Mazyar Shadman, MD, MPH Selection of Bruton’s tyrosine kinase (BTK) inhibitor therapy in CLL patients requires recognizing key differences between first- and next-generation agents in terms of the safety profile and efficacy across all pat

Host: Mazyar Shadman, MD, MPH Selection of Bruton’s tyrosine kinase (BTK) inhibitor therapy in CLL patients requires recognizing key differences between first- and next-generation agents in terms of the safety profile and efficacy across all pat

Host: Marianna Fontana, MD Guest: Ronald Witteles, MD Struggling to manage ATTR-CM? Our faculty are exploring the key considerations shaping current clinical trial design and how innovations might change our approach to the management of ATT

Host: Javier Cortes, MD, PhD Guest: Komal Jhaveri, MD, FACP The addition of antibody-drug conjugate (ADC) therapies to the treatment armamentarium for endocrine-refractory, HR-positive, HER2-negative metastatic breast cancer has greatly impr

Host: Arshad M. Khanani, MD, MA Guest: Karl Csaky, MD, PhD Guest: Christina Y. Weng, MD, MBA, FASRS Anti-vascular endothelial growth factor (VEGF) therapy acts on only 1 of the multiple pathways involved in the pathophysiology of retinal

Host: Nabil F. Saba, MD, FACP Guest: Barbara Burtness, MD In this series, Drs. Nabil Saba and Barbara Burtness review best practices for the use of immune checkpoint therapies in the treatment of head and neck squamous cell carcinoma. They d